- Home
- LPCN vs ICU Comparison
LPCN vs ICU Comparison
Compare LPCN & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPCN | ICU |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 13.8M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPCN | ICU |
|---|---|---|
| Price | $2.28 | $3.07 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.7K | ★ 69.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,976,677.00 | $1,234,000.00 |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | $92.00 | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $1.81 | $0.22 |
| 52 Week High | $12.37 | $5.38 |
Technical Indicators
Market Signals| Indicator | LPCN | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 38.71 |
| Support Level | $2.16 | $2.96 |
| Resistance Level | $2.27 | $4.96 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 82.14 | 2.65 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.